Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof

• US 20070292359A1
• Filed: 06/07/2007
• Published: 12/20/2007
• Est. Priority Date: 10/25/2002
• Status: Abandoned Application

• Current Assignee: Foamix Pharmaceuticals, Ltd. (VYNE Therapeutics, Inc.)
• Original Assignee: Foamix Ltd. (VYNE Therapeutics, Inc.)
• Inventors: Schuz, David, Berman, Tal, Friedman, Doron, Tamarkin, Dov, Feiman, Naomi
• Application Number:
  US11/811,140
• Publication Number:
  US 20070292359A1
• Time in Patent Office: Days
• US Class Current: 424/47
• CPC Class Codes: A01N 25/16 Foams
• CPC Class Codes: A01N 53/00 Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
• CPC Class Codes: A61K 8/046 Aerosols; Foams
• CPC Class Codes: A61K 8/86 Polyethers
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 33/14 Ectoparasiticides, e.g. scabicides
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61Q 19/007 Preparations for dry skin
• CPC Class Codes: A61Q 19/008 Preparations for oily skin
• CPC Class Codes: A61Q 19/02 for chemically bleaching or whitening the skin
• CPC Class Codes: A61Q 19/06 for countering cellulitis
• CPC Class Codes: A61Q 5/006 Antidandruff preparations

Abstract

The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof. The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof.

Claims

1. A foamable pharmaceutical carrier comprising:

a polypropylene glycol alkyl ether of about 3% to about 90% by weight of the total composition;

a surface-active agent;

a solvent; and

a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

2. The foamable carrier of claim 1, wherein the alkyl ether is a stearyl ether.

3. The foamable carrier of claim 1, wherein said polypropylene glycol alkyl ether concentration is higher than about 15%.

4. The foamable carrier of claim 1, wherein said concentration is higher than about 20%.

5. The foamable carrier of claim 1, wherein said concentration is higher than about 30%.

6. The foamable carrier of claim 1, wherein said concentration is higher than about 40%.

7. The foamable carrier of claim 1, wherein said concentration is higher than about 50%.

8. The foamable carrier of claim 1, wherein said concentration is higher than about 60%.

9. The foamable carrier of claim 1, wherein said concentration is higher than about 70%.

10. The foamable carrier of claim 1, wherein said concentration is higher than about 80%.

11. The foamable carrier of claim 1 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof.

12. The foamable carrier of claim 11 wherein the solvent comprises water.

13. The foamable carrier of claim 1, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

14. The foamable carrier of claim 1, further comprising a polymeric agent.

15. The foamable carrier of claim 14, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

16. The foamable carrier of claim 15, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

17. The foamable carrier of claim 1, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

18. The foamable carrier of claim 17, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

19. The foamable carrier of claim 17, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

20. The foamable carrier of claim 1, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

21. The foamable carrier of claim 20, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

22. The foamable carrier of claim 20, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

23. The foamable carrier of claim 21 or 22, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

24. The foamable carrier of claim 1, being in a form of an emulsion.

25. The foamable carrier of claim 24, wherein the emulsion is an oil in water emulsion.

26. The foamable carrier of claim 24, wherein the emulsion is a water in oil emulsion.

27. The foamable carrier of claim 1, wherein the surface active agent comprises a non-ionic surface active agent.

28. The foamable carrier of claim 27, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

29. The foamable carrier of claim 28 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

30. The foamable carrier of claim 1 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

31. The foamable carrier of claim 1 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

32. The foamable carrier of claim 1 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

33. The foamable carrier of claim 1 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

34. The foamable carrier of claim 1, wherein the surface active agent comprises a non-ionic surfactant.

35. The foamable carrier of claim 34, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwitterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

36. The foamable carrier of claim 13, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

37. The foamable carrier of claim 1, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

38. The foamable composition of claim 1 which is substantially non alcoholic.

39. The foamable composition of claim 1 which is substantially non aqueous.

40. The foamable composition of claim 1 further comprising a modulating agent.

41. The foamable carrier of claim 1, further comprising a foam adjuvant.

42. The foamable carrier of claim 1, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

43. The foamable carrier of claim 42, wherein the fatty triglyceride is cocoglyceride.

44. The foamable carrier of claim 1, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.

45. The foamable carrier of claim 1, wherein said foamable carrier is selected from the group consisting of oil-in-water emulsions, water-in-oil emulsions, waterless oleaginous formulations, waterless polyethylene glycol and propylene glycol based compositions, waterless silicone in polyethylene glycol based compositions and waterless silicone in propylene glycol based compositions.

55. The foamable therapeutic composition of claim 51.1, wherein said concentration is higher than about 80%.

46. A foamable therapeutic composition comprising:

a therapeutically effective amount of an active agent;

a polypropylene glycol alkyl ether of about 3% to about 90% by weight of the total composition;

a surface-active agent;

a solvent; and

a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

47. The foamable therapeutic composition of claim 46, wherein the alkyl ether is a stearyl ether.

56. The foamable therapeutic composition of claim 46 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof

57. The foamable therapeutic composition of claim 56, wherein the solvent comprises water.

58. The foamable therapeutic composition of claim 46, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

59. The foamable therapeutic composition of claim 46, wherein the active agent is selected from the group consisting of active herbal extracts, acaroids, age spot and keratosis removing agents, allergen, analgesics, local anesthetics, anticancer agents, antiallergic agents, ant aging agents, antibacterial, antibiotics, antigun agents, anticancer agents, antidandruff agents, antidepressants, ant dermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, asoconstrictors, vasodilators, vitamins, vitamin D derivatives, wound healing agents, wart removers, an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid;

vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative,vitamin D, a vitamin D derivative;

vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, benzoyl chloride, calcium hypochlorite, magnesium hypochlorite, an anti-wrinkle agent, a radical scavenger, a metal, silver, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, talc, carbon, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.

60. The foamable therapeutic composition of claim 46, wherein the active agent is a vitamin D derivative, at a concentration between about 0.001% and about 0.02% by weight.

61. The foamable therapeutic composition of claim 46, wherein the active agent is selected from the group comprising of:

Hydrocortisone acetate, Betamethasone valerate, Clobetasol proprionate, Acyclovir, Ciclopirox, Clindamycin, Azelaic acid, Metronidazol, Diclofenac, Tacrolimus, Caffeine, Clotrimazole, Lidocaine base, Terbinafine HCL, Gentamycin, Dexpanthenol, Urea, Ammonium lactate, Povidone-iodine, Permethrine.

62. The foamable therapeutic composition of claim 46, wherein the active agent is a permethrin.

63. The foamable therapeutic composition of claim 62, wherein the active agent is a permethrin, at a concentration between about 1% and about 8% by weight.

64. The foamable therapeutic composition of claim 46, wherein the active agent is a permethrin, at a concentration of about 5% by weight.

65. The foamable therapeutic composition of claim 46, further comprising a polymeric agent.

66. The foamable therapeutic composition of claim 65, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

67. The foamable therapeutic composition of claim 66, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

68. The foamable therapeutic composition of claim 46, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

69. The foamable therapeutic composition of claim 68, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

70. The foamable therapeutic composition of claim 68, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

71. The foamable therapeutic composition of claim 46, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

72. The foamable therapeutic composition of claim 71, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes

73. The foamable therapeutic composition of claim 71, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

74. The foamable therapeutic composition of claim 72 and 73, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

75. The foamable therapeutic composition of claim 46, being in a form of an emulsion.

76. The foamable therapeutic composition of claim 75, wherein the emulsion is an oil in water emulsion.

77. The foamable therapeutic composition of claim 76, wherein the emulsion is a water in oil emulsion.

78. The foamable therapeutic composition of claim 46, wherein the surface active agent comprises a non-ionic surface active agent.

79. The foamable therapeutic composition of claim 78, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

80. The foamable therapeutic composition of claim 78 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

81. The foamable therapeutic composition of claim 46 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

82. The foamable therapeutic composition of claim 46 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

83. The foamable therapeutic composition of claim 46 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

84. The foamable therapeutic composition of claim 46 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

85. The foamable therapeutic composition of claim 46, wherein the surface active agent comprises a non-ionic surfactant.

86. The foamable therapeutic composition of claim 46, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwitterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

88. The foamable therapeutic composition of claim 46, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

89. The foamable composition of claim 46 which is substantially non alcoholic.

90. The foamable composition of claim 46 which is substantially non aqueous.

91. The foamable composition of claim 46 further comprising a modulating agent.

92. The foamable therapeutic composition of claim 46, further comprising a foam adjuvant.

93. The foamable therapeutic composition of claim 46, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

94. The foamable therapeutic composition of claim 93, wherein the fatty triglyceride is cocoglyceride.

95. The foamable therapeutic composition of claim 46, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.

48. The foamable therapeutic composition of claim 48, wherein said concentration is higher than about 15%.

49. The foamable therapeutic composition of claim 48, wherein said concentration is higher than about 20%.

50. The foamable therapeutic composition of claim 49, wherein said concentration is higher than about 30%.

51. The foamable therapeutic composition of claim 50, wherein said concentration is higher than about 40%.

52. The foamable therapeutic composition of claim 51, wherein said concentration is higher than about 50%.

53. The foamable therapeutic composition of claim 52, wherein said concentration is higher than about 60%.

54. The foamable therapeutic composition of claim 52, wherein said concentration is higher than about 70%.

87. The foamable therapeutic composition of claim 48, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

96. A method of treating a disorder of a mammalian subject, comprising:

administering a foamable therapeutic composition to a target site, the composition comprising;

a therapeutically effective concentration of an active agent;

a polypropylene glycol (PPG) alkyl ether of about 3% to about 90% by weight of the total composition;

a surface-active agent;

a solvent; and

a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

97. The method of claim 96, wherein the alkyl ether is a stearyl ether.

98. The method of claim 96, wherein the target site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.

99. The method of claim 96, wherein the disorder is selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, granuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi'"'"'s sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet'"'"'s syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranuloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VI N), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn'"'"'s disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum;

and wherein the active agent is suitable for treating said disorder.

100. The method of claim 96, wherein the disorder is psoriasis;

and wherein the active agent is a vitamin D derivative, at a concentration between about 0.001% and about 0.02% by weight.

101. The method of claim 96, wherein the active agent is a permethrin.

102. The method of claim 101, wherein the active agent is a permethrin, at a concentration between about 1% and about 8% by weight.

103. The method of claim 96, wherein said active agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid;

vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative,vitamin D, a vitamin D derivative;

vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, benzoyl chloride, calcium hypochlorite, magnesium hypochlorite, an anti-wrinkle agent, a radical scavenger, a metal, silver, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, talc, carbon, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.

104. The method of claim 96, wherein said active agent is selected from the group comprising of:

Hydrocortisone acetate, Betamethasone valerate, Clobetasol proprionate, Acyclovir, Ciclopirox, Clindamycin, Azelaic acid, Metronidazol, Diclofenac, Tacrolimus, Caffeine, Clotrimazole, Lidocaine base, Terbinafine HCL, Gentamycin, Dexpanthenol, Urea, Ammonium lactate, Povidone-iodine and Permethrine.

105. The method of claim 96, wherein the alkyl ether is a stearyl ether.

114. The method of claim 96 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof.

115. The method of claim 114 wherein the solvent comprises water.

116. The method of claim 96, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

117. The method of claim 96, further comprising a polymeric agent.

118. The method of claim 117, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

119. The method of claim 118, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

120. The method of claim 96, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

121. The method of claim 96, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

122. The method of claim 120, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

123. The method of claim 96, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

124. The method of claim 123, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes

125. The method of claim 123, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

126. The method of claim 124 or 125, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

127. The method of claim 96, being in a form of an emulsion.

128. The method of claim 127, wherein the emulsion is an oil in water emulsion.

129. The method of claim 127, wherein the emulsion is a water in oil emulsion.

130. The method of claim 96, wherein the surface active agent comprises a non-ionic surface active agent.

131. The method of claim 130, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

132. The method of claim 130 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

133. The method of claim 96 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

134. The method of claim 96 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

135. The method of claim 96 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

136. The method of claim 96 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

137. The method of claim 96, wherein the surface active agent comprises a non-ionic surfactant.

138. The method of claim 137, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwifterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

139. The method of claim 116, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

140. The method of claim 96, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

141. The foamable composition of claim 96 which is substantially non alcoholic.

142. The foamable composition of claim 96 which is substantially non aqueous.

143. The foamable composition of claim 96 further comprising a modulating agent.

144. The method of claim 96, further comprising a foam adjuvant.

145. The method of claim 96, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

146. The method of claim 145, wherein the fatty triglyceride is cocoglyceride.

147. The method of claim 96, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.

106. The method of claim 106, wherein said concentration is higher than about 15%.

107. The method of claim 106, wherein said concentration is higher than about 20%.

108. The method of claim 107, wherein said concentration is higher than about 30%.

109. The method of claim 108, wherein said concentration is higher than about 40%.

110. The method of claim 109, wherein said concentration is higher than about 50%.

111. The method of claim 110, wherein said concentration is higher than about 60%.

112. The method of claim 111, wherein said concentration is higher than about 70%.

113. The method of claim 112, wherein said concentration is higher than about 80%.

148. A foamable pharmaceutical carrier comprising at least 15% polypropylene glycol alkyl ether and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

149. The foamable carrier of claim 148, wherein the alkyl ether is a stearyl ether.

150. The foamable carrier of claim 148, wherein the concentration of the polypropylene glycol alkyl ether, is between about 3% and about 90%.

151. The foamable carrier of claim 150, wherein said concentration is higher than about 15%.

152. The foamable carrier of claim 151, wherein said concentration is higher than about 20%.

153. The foamable carrier of claim 152, wherein said concentration is higher than about 30%.

154. The foamable carrier of claim 153, wherein said concentration is higher than about 40%.

155. The foamable carrier of claim 154, wherein said concentration is higher than about 50%.

156. The foamable carrier of claim 155, wherein said concentration is higher than about 60%.

157. The foamable therapeutic composition of claim 156, wherein said concentration is higher than about 70%.

158. The foamable therapeutic composition of claim 157, wherein said concentration is higher than about 80%.

159. The foamable carrier of claim 148, further comprising a solvent.

160. The foamable carrier of claim 159 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof.

161. The foamable carrier of claim 160 wherein the solvent comprises water.

162. The foamable carrier of claim 148, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

163. The foamable carrier of claim 148, further comprising a polymeric agent.

164. The foamable carrier of claim 163, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

165. The foamable carrier of claim 164, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

166. The foamable carrier of claim 148, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

167. The foamable carrier of claim 148, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

168. The foamable carrier of claim 166, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

169. The foamable carrier of claim 148, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

170. The foamable carrier of claim 169, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes

171. The foamable carrier of claim 170, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

172. The foamable carrier of claim 148, being in a form of an emulsion.

173. The foamable carrier of claim 172, wherein the emulsion is an oil in water emulsion.

174. The foamable carrier of claim 172, wherein the emulsion is a water in oil emulsion.

175. The foamable carrier of claim 148, further comprising a surface active agent.

176. The foamable carrier of claim 175, wherein the surface active agent comprises a non-ionic surface active agent.

177. The foamable carrier of claim 176, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

178. The foamable carrier of claim 177 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

179. The foamable carrier of claim 175 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

180. The foamable carrier of claim 175 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

181. The foamable carrier of claim 175 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

182. The foamable carrier of claim 175 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

183. The foamable carrier of claim 175, wherein the surface active agent comprises a non-ionic surfactant.

184. The foamable carrier of claim 183, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwitterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

185. The foamable carrier of claim 162, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

186. The foamable carrier of claim 148, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

187. The foamable composition of claim 148 which is substantially non alcoholic.

188. The foamable composition of claim 148 which is substantially non aqueous.

189. The foamable composition of claim 148 further comprising a modulating agent.

190. The foamable carrier of claim 148, further comprising a foam adjuvant.

191. The foamable carrier of claim 148, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

192. The foamable carrier of claim 191, wherein the fatty triglyceride is cocoglyceride.

193. The foamable carrier of claim 148, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.

194. The foamable carrier of claim 148, wherein said foamable carrier is selected from the group consisting of oil-in-water emulsions, water-in-oil emulsions, waterless oleaginous formulations, waterless polyethylene glycol and propylene glycol based compositions, waterless silicone in polyethylene glycol based compositions and waterless silicone in propylene glycol based compositions.

195. A foamable therapeutic composition comprising:

a therapeutically effective amount of an active agent;

at least 15% polypropylene glycol alkyl ether and

a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

196. The foamable therapeutic composition of claim 195, wherein the alkyl ether is a stearyl ether.

197. The foamable therapeutic composition of claim 195, wherein the concentration of the polypropylene glycol alkyl ether, is between about 1% and about 90%.

198. The foamable therapeutic composition of claim 197, wherein said concentration is higher than about 15%.

199. The foamable therapeutic composition of claim 198, wherein said concentration is higher than about 20%.

200. The foamable therapeutic composition of claim 199, wherein said concentration is higher than about 30%.

201. The foamable therapeutic composition of claim 200, wherein said concentration is higher than about 40%.

202. The foamable therapeutic composition of claim 201, wherein said concentration is higher than about 50%.

203. The foamable therapeutic composition of claim 202, wherein said concentration is higher than about 60%.

204. The foamable therapeutic composition of claim 203, wherein said concentration is higher than about 70%.

205. The foamable therapeutic composition of claim 204, wherein said concentration is higher than about 80%.

206. The foamable therapeutic composition of claim 195 further comprising a solvent.

207. The foamable therapeutic composition of claim 195 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof

208. The foamable therapeutic composition of claim 207, wherein the solvent comprises water.

209. The foamable therapeutic composition of claim 195, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

210. The foamable therapeutic composition of claim 195, wherein the active agent is selected from the group consisting of active herbal extracts, acaroids, age spot and keratosis removing agents, allergen, analgesics, local anesthetics, anticancer agents, antiallergic agents, ant aging agents, antibacterial, antibiotics, antigun agents, anticancer agents, antidandruff agents, antidepressants, ant dermatitis agents, antiedemics, antihistamines, antihelminths, antihyperkeratolyte agents, antiinflammatory agents, antiirritants, antilipemics, antimicrobials, antimycotics, antiproliferative agents, antioxidants, anti-wrinkle agents, antipruritics, antipsoriatic agents, antirosacea agents antiseborrheic agents, antiseptic, antiswelling agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, insecticides, insect repellents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non-steroidal anti-inflammatory agents, oxidizing agents, pediculicides, photodynamic therapy agents, retinoids, sanatives, scabicides, self tanning agents, skin whitening agents, asoconstrictors, vasodilators, vitamins, vitamin D derivatives, wound healing agents, wart removers, an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid;

vitamin A, a vitamin A derivative, vitamin B., a vitamin B derivative, vitamin C, a vitamin C derivative,vitamin D, a vitamin D derivative;

vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, benzoyl chloride, calcium hypochlorite, magnesium hypochlorite, an anti-wrinkle agent, a radical scavenger, a metal, silver, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, talc, carbon, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.

211. The foamable therapeutic composition of claim 195, wherein the active agent is a vitamin D derivative, at a concentration between about 0.001% and about 0.02% by weight.

212. The foamable therapeutic composition of claim 195, wherein the active agent is selected from the group comprising of:

Hydrocortisone acetate, Betamethasone valerate, Clobetasol proprionate, Acyclovir, Ciclopirox, Clindamycin, Azelaic acid, Metronidazol, Diclofenac, Tacrolimus, Caffeine, Clotrimazole, Lidocaine base, Terbinafine HCL, Gentamycin, Dexpanthenol, Urea, Ammonium lactate, Povidone-iodine, Permethrine.

213. The foamable therapeutic composition of claim 195, wherein the active agent is a permethrin.

214. The foamable therapeutic composition of claim 213, wherein the active agent is a permethrin, at a concentration between about 1% and about 8% by weight.

215. The foamable therapeutic composition of claim 195, wherein the active agent is a permethrin, at a concentration of about 5% by weight.

216. The foamable therapeutic composition of claim 195, further comprising a polymeric agent.

217. The foamable therapeutic composition of claim 216, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

218. The foamable therapeutic composition of claim 217, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

219. The foamable therapeutic composition of claim 195, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

220. The foamable therapeutic composition of claim 195, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

221. The foamable therapeutic composition of claim 219, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

222. The foamable therapeutic composition of claim 195, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

223. The foamable therapeutic composition of claim 222, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes

224. The foamable therapeutic composition of claim 222, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

225. The foamable therapeutic composition of claim 223 or 224, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

226. The foamable therapeutic composition of claim 195, being in a form of an emulsion.

227. The foamable therapeutic composition of claim 226, wherein the emulsion is an oil in water emulsion.

228. The foamable therapeutic composition of claim 227, wherein the emulsion is a water in oil emulsion.

229. The foamable therapeutic composition of claim 195, further comprising a surface active agent.

230. The foamable therapeutic composition of claim 229, wherein the surface active agent comprises a non-ionic surface active agent.

231. The foamable therapeutic composition of claim 230, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

232. The foamable therapeutic composition of claim 230 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

233. The foamable therapeutic composition of claim 229 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

234. The foamable therapeutic composition of claim 229 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

235. The foamable therapeutic composition of claim 229 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

236. The foamable therapeutic composition of claim 229 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

237. The foamable therapeutic composition of claim 229, wherein the surface active agent comprises a non-ionic surfactant.

238. The foamable therapeutic composition of claim 229, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwitterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

239. The foamable therapeutic composition of claim 197, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

240. The foamable therapeutic composition of claim 195, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

241. The foamable composition of claim 195 which is substantially non alcoholic.

242. The foamable composition of claim 195 which is substantially non aqueous.

243. The foamable composition of claim 195 further comprising a modulating agent.

244. The foamable therapeutic composition of claim 195, further comprising a foam adjuvant.

245. The foamable therapeutic composition of claim 195, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

246. The foamable therapeutic composition of claim 245, wherein the fatty triglyceride is cocoglyceride.

247. The foamable therapeutic composition of claim 195, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.

258. The method of claim 244, wherein said concentration is higher than about 20%.

259. The method of claim 258, wherein said concentration is higher than about 30%.

260. The method of claim 259, wherein said concentration is higher than about 40%.

261. The method of claim 260, wherein said concentration is higher than about 50%.

262. The method of claim 261, wherein said concentration is higher than about 60%.

263. The method of claim 262, wherein said concentration is higher than about 70%.

264. The method of claim 263, wherein said concentration is higher than about 80%.

248. A method of treating a disorder of a mammalian subject, comprising:

administering a foamable therapeutic composition to a target site, the composition comprising;

a therapeutically effective concentration of an active agent;

at least 15% polypropylene glycol alkyl ether and

a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

249. The method of claim 248, wherein the alkyl ether is a stearyl ether.

250. The method of claim 248, wherein the target site is selected from the group consisting of the skin, a body cavity, a mucosal surface, the nose, the mouth, the eye, the ear canal, the respiratory system, the vagina and the rectum.

251. The method of claim 248, wherein the disorder is selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, granuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi'"'"'s sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet'"'"'s syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, and vitiligo, chlamydia infection, gonorrhea infection, hepatitis B, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranuloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn'"'"'s disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum;

and wherein the active agent is suitable for treating said disorder.

252. The method of claim 248, wherein the disorder is psoriasis;

and wherein the active agent is a vitamin D derivative, at a concentration between about 0.001% and about 0.02% by weight.

253. The method of claim 248, wherein the active agent is a permethrin.

254. The method of claim 253, wherein the active agent is a permethrin, at a concentration between about 1% and about 8% by weight.

255. The method of claim 248, wherein said active agent is selected from the group consisting of an anti-infective, an antibiotic, an antibacterial agent, an antifungal agent, an antiviral agent, an antiparasitic agent, an immunosuppressive agent, an immunomodulator, an immunoregulating agent, a hormonal agent, a steroid;

vitamin A, a vitamin A derivative, vitamin B, a vitamin B derivative, vitamin C, a vitamin C derivative,vitamin D, a vitamin D derivative;

vitamin E, a vitamin E derivative, vitamin F, a vitamin F derivative, vitamin K, a vitamin K derivative, a wound healing agent, a disinfectant, an anesthetic, an antiallergic agent, an alpha hydroxyl acid, lactic acid, glycolic acid, a beta-hydroxy acid, a protein, a peptide, a neuropeptide, a allergen, an immunogenic substance, a haptene, an oxidizing agent, an antioxidant, a dicarboxylic acid, azelaic acid, sebacic acid, adipic acid, fumaric acid, a retinoid, an antiproliferative agent, an anticancer agent, a photodynamic therapy agent, benzoyl chloride, calcium hypochlorite, magnesium hypochlorite, an anti-wrinkle agent, a radical scavenger, a metal, silver, a metal oxide, titanium dioxide, zinc oxide, zirconium oxide, iron oxide, silicone oxide, talc, carbon, an anti wrinkle agent, a skin whitening agent, a skin protective agent, a masking agent, an anti-wart agent, a refatting agent, a lubricating agent and mixtures thereof.

256. The method of claim 248, wherein said active agent is selected from the group comprising of:

Hydrocortisone acetate, Betamethasone valerate, Clobetasol proprionate, Acyclovir, Ciclopirox, Clindamycin, Azelaic acid, Metronidazol, Diclofenac, Tacrolimus, Caffeine, Clotrimazole, Lidocaine base, Terbinafine HCL, Gentamycin, Dexpanthenol, Urea, Ammonium lactate, Povidone-iodine, Permethrine.

257. The method of claim 248, wherein the concentration of the polypropylene glycol alkyl ether, is between about 15% and about 90%.

265. The method of claim 248 further comprising a solvent.

266. The method of claim 265 wherein the solvent is selected from the group consisting of water;

a hydrophilic solvent;

a hydrophobic solvent;

a potent solvent;

a silicone, an emollient, a co-solvent, and mixtures thereof.

267. The method of claim 266 wherein the solvent comprises water.

268. The method of claim 248, further containing at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight.

269. The method of claim 248, further comprising a polymeric agent.

270. The method of claim 269, wherein the polymeric agent is selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent.

271. The method of claim 270, wherein the polymeric agent is selected from the group consisting of locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, guar gum, cationic guars, hydroxypropyl guar gum, starch, an amine-bearing polymer, chitosan, alginic acid, hyaluronic acid, a chemically modified starch, a carboxyvinyl polymer, polyvinylpyrrolidone, polyvinyl alcohol, a polyacrylic acid polymer, a polymethacrylic acid polymer, polyvinyl acetate, a polyvinyl chloride polymer, a polyvinylidene chloride polymer, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxy propylmethyl cellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcarboxymethylcellulose, carboxymethyl cellulose, carboxymethylcellulose carboxymethylhydroxyethylcellulose, a cationic cellulose PEG 1000, PEG 4000, PEG 6000 and PEG 8000.

272. The method of claim 248, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

273. The method of claim 248, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

274. The method of claim 272, which is substantially resistant to one or more Freeze-Thaw cycles (FTC).

275. The method of claim 248, which is substantially flowable and housed in a presurissed canister, wherein upon actuation and release therefrom, the composition expands to form a breakable shear sensitive foam.

276. The method of claim 275, which is substantially resistant to centrifugation of upto about 3000 rpm for at least 3 minutes.

277. The method of claim 275, which is substantially resistant to centrifugation of upto about 1000 rpm for at least 3 minutes.

278. The method of claim 276 or 277, which is substantially resistant to one or more Freeze Thaw cycles (FTCs).

279. The method of claim 248, being in a form of an emulsion.

280. The method of claim 279, wherein the emulsion is an oil in water emulsion.

281. The method of claim 279, wherein the emulsion is a water in oil emulsion.

282. The method of claim 248, further comprising a surface active agent.

283. The method of claim 282, wherein the surface active agent comprises a non-ionic surface active agent.

284. The method of claim 283, wherein the surface active agent is selected from the group consisting of a polysorbate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, a polyoxyethylene fatty acid ester, Myrj 45, Myrj 49, Myrj 52 and Myrj 59;

a polyoxyethylene alkylyl ether, polyoxyethylene cetyl ether, polyoxyethylene palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1, a sucrose ester, a partial ester of sorbitol, sorbitan monolaurate, sorbitan monolaurate a monoglyceride, a diglyceride, isoceteth-20 and a sucrose ester.

285. The method of claim 283 wherein the surface active agent is selected from the group consisting of steareth 2, glyceryl monostearate/PEG 100 stearate, Glyceryl Stearate, Steareth-21, peg 40 stearate, polysorbate 80, sorbitan stearate, aureth 4, Sorbitan monooleate, ceteareth 20, steareth 20, ceteth 20, Macrogol Cetostearyl Ether, ceteth 2, PEG-30 Dipolyhydroxystearate, sucrose distearate, polyoxyethylene (100) stearate, or mixtures of two or more thereof.

286. The method of claim 282 wherein the surface-active agent has a HLB value between about 2 and about 9 or is combination of two or more surface active agents having a mean HLB value between about 2 and about 9.

287. The method of claim 282 wherein the surface-active agent has a HLB value between about 7 and about 14 or is combination of two or more surface active agents having a mean HLB value between about 7 and about 14.

288. The method of claim 282 wherein the surface-active agent has a HLB value between about 9 and about 19 or is combination of two or more surface active agents having a mean HLB value between about 9 and about 19.

289. The method of claim 282 wherein the surface-active agent is a solid, a liquid or a mixture thereof.

290. The method of claim 282, wherein the surface active agent comprises a non-ionic surfactant.

291. The method of claim 290, wherein the surface active agent further comprises an ionic surfactant, selected from the group consisting of a cationic surfactant, a zwitterionic surfactant, an amphoteric surfactant and an ampholytic surfactant.

292. The method of claim 268, wherein the hydrophobic organic solvent is selected from the group consisting of mineral oil, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl dimerate, maleated soybean oil, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, unsaturated or polyunsaturated oils, such as olive oil, corn oil, soybean oil, canola oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, flaxseed oil, wheat germ oil, evening primrose oils;

essential oils; and

silicone oils, such as dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer.

293. The method of claim 248, further comprising a foam adjuvant selected from the group consisting of a fatty alcohol, a fatty acid and a hydroxyl fatty acid.

294. The foamable composition of claim 248 which is substantially non alcoholic.

295. The foamable composition of claim 248 which is substantially non aqueous.

296. The foamable composition of claim 248 further comprising a modulating agent.

297. The method of claim 248, further comprising a foam adjuvant.

298. The method of claim 248, further comprising a solid fat, a solid lipid, a solid triglyceride or mixtures thereof.

299. The method of claim 298, wherein the fatty triglyceride is cocoglyceride.

300. The method of claim 248, further comprising an additional component selected from the group consisting of an anti perspirant, an anti-static agent, a buffering agent, a bulking agent;

a chelating agent, a colorant, a conditioner, a deodorant, a diluent, a dye, an emollient, fragrance, a humectant, an occlusive agent, a penetration enhancer, a perfuming agent, a permeation enhancer, a pH-adjusting agent, a preservative, a skin penetration enhancer, a sunscreen, a sun blocking agent, a sunless tanning agent, and a vitamins.